Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Restoring neuropetide Y levels in the hypothalamus ameliorates premature aging phenotype in mice

Ferreira-Marques M., Carmo-Silva S., Pereira J., Botelho M., Nóbrega C., López-Otín C.

Animal Study on Hair Loss, published in Geroscience (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Geroscience (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40011349
PMCID
PMC12397475
DOI
10.1007/s11357-025-01574-0
Citations
1

Abstract (original English)

The hypothalamus has been recognized as a regulator of whole-body aging. Neuropeptide Y (NPY), highly abundant in the central nervous system and produced by the hypothalamus, enhances autophagy in this brain region and mediates autophagy triggered by caloric restriction, suggesting a potential role as a caloric restriction mimetic and an aging regulator. Considering that hypothalamic NPY levels decline during aging, we investigated if reestablishment of NPY levels mitigate aging phenotype, using a mouse model of premature aging - Zmpste24 -/- mouse. The results show that reestablishing hypothalamic NPY levels delayed aging-associated features, including lipodystrophy, alopecia, and memory. Moreover, these results suggest that strategies that promote maintenance of hypothalamic NPY levels might be relevant to counteract aging progression and age-related deteriorations.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HypothalamusAnimalsMice, Inbred C57BLMice, KnockoutMiceDisease Models, AnimalAging, PrematureNeuropeptide YCaloric RestrictionAging

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research